The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation

Critical Care

Volumn 17, Issue 6, 2013, Pages

  Peigne, Vincent ^a,b   Azoulay, Elie ^b   Coquet, Isaline ^b   Mariotte, Eric ^a,b   Darmon, Michael ^b   Legendre, Paulette ^a   Adoui, Nadir ^b   Marfaing Koka, Anne ^a,c   Wolf, Martine ^a,c   Schlemmer, Benoit ^b   Veyradier, Agnès ^a,c  

^a Dept Environ Med Natl Inst Publ HIth   (Norway)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERTENSIVE FACTOR; INTERLEUKIN 6; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; BIOLOGICAL MARKER; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE; VON WILLEBRAND FACTOR;

A DISINTEGRIN AND METALLOPROTEASE WITH THROMBOSPONDIN TYPE 1 REPEAT MEMBER 13 DEFICIENCY; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME ACTIVITY; ENZYME DEFICIENCY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; RENAL REPLACEMENT THERAPY; SEPTIC SHOCK; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; APACHE; BLOOD; DEFICIENCY; FEMALE; FRANCE; MALE; MORTALITY; MULTIVARIATE ANALYSIS; ORGAN DYSFUNCTION SCORE; PROGNOSIS; SHOCK, SEPTIC; SURVIVAL;

ADAM PROTEINS; AGED; APACHE; BIOLOGICAL MARKERS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FRANCE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGAN DYSFUNCTION SCORES; PROGNOSIS; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; RESPIRATION, ARTIFICIAL; SHOCK, SEPTIC; SURVIVAL ANALYSIS; VASOCONSTRICTOR AGENTS; VASOPRESSINS; VON WILLEBRAND FACTOR;

EID: 84892154429     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13115     Document Type: Article

References (59)

1. Bone RC. Sepsis and coagulation. An important link. Chest 1992, 101:594-596.
2. Aird WC. Sepsis and coagulation. Crit Care Clin 2005, 21:417-431. 10.1016/j.ccc.2005.04.004, 15992665.
3. Diehl JL, Borgel D. Sepsis and coagulation. Curr Opin Crit Care 2005, 11:454-460.
4. Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003, 16:43-47.
5. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007, 35:2191-2195. 10.1097/01.CCM.0000281468.94108.4B, 17855836.
6. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999, 341:586-592. 10.1056/NEJM199908193410807, 10451465.
7. Borgel D, Bornstain C, Reitsma PH, Lerolle N, Gandrille S, Dali-Ali F, Esmon CT, Fagon JY, Aiach M, Diehl JL. A comparative study of the protein c pathway in septic and non-septic patients with organ failure. Am J Respir Crit Care Med 2007, 176:878-885. 10.1164/rccm.200611-1692OC, 17673691.
8. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992, 101:816-823. 10.1378/chest.101.3.816, 1531791.
9. Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002, 30:1729-1734. 10.1097/00003246-200208000-00009, 12163784.
10. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003, 290:238-247. 10.1001/jama.290.2.238, 12851279.
11. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin iii in severe sepsis: A randomized controlled trial. JAMA 2001, 286:1869-1878. 10.1001/jama.286.15.1869, 11597289.
12. Kayal S, Jais JP, Aguini N, Labrousse J. Elevated circulating e-selectin, intercellular adhesion molecule 1, and von willebrand factor in patients with severe infection. Am J Respir Crit Care Med 1998, 157:776-784. 10.1164/ajrccm.157.3.9705034, 9517590.
13. Ware LB, Eisner MD, Thompson BT, Parsons PE, Matthay MA. Significance of von willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med 2004, 170:766-772. 10.1164/rccm.200310-1434OC, 15201135.
14. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. Von willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998, 339:1578-1584. 10.1056/NEJM199811263392202, 9828245.
15. Tsai HM, Lian EC. Antibodies to von willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339:1585-1594. 10.1056/NEJM199811263392203, 3159001, 9828246.
16. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985, 38:469-479. 10.1016/0049-3848(85)90180-X, 2861671.
17. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002, 347:589-600. 10.1056/NEJMra020528, 12192020.
18. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Frémeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004, 83:233-244. 10.1097/01.md.0000133622.03370.07, 15232311.
19. Coppo P, Adrie C, Azoulay E, Leleu G, Oksenhendler E, Galicier L, Le Gall JR, Bussel A, Schlemmer B. Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit (icu) patients?. Intensive Care Med 2003, 29:564-569.
20. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of von willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood 2006, 107:528-534. 10.1182/blood-2005-03-1087, 16189276.
21. Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, Deckmyn H, Legendre P, Diehl JL, Baruch D. Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007, 35:2375-2382. 10.1097/01.CCM.0000284508.05247.B3, 17944029.
22. Levy B, Lacolley P, Regnault V. ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin) and endothelial dysfunction in sepsis: marker or culprit?. Crit Care Med 2007, 35:2453-2454. 10.1097/01.CCM.0000284735.46290.05, 17885389.
23. Hovinga JA, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, Hack CE, ten Cate H, Reitsma PH, Wuillemin WA, Lämmle B. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007, 5:2284-2290. 10.1111/j.1538-7836.2007.02743.x, 17764538.
24. Bockmeyer CL, Claus RA, Budde U, Kentouche K, Schneppenheim R, Lösche W, Reinhart K, Brunkhorst FM. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008, 93:137-140. 10.3324/haematol.11677, 18166799.
25. Claus RA, Bockmeyer CL, Budde U, Kentouche K, Sossdorf M, Hilberg T, Schneppenheim R, Reinhart K, Bauer M, Brunkhorst FM, Lösche W. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009, 101:239-247.
26. Hyun J, Kim HK, Kim JE, Lim MG, Jung JS, Park S, Cho HI. Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation. Thromb Res 2009, 124:75-79. 10.1016/j.thromres.2008.11.020, 19162307.
27. Nguyen TC, Liu A, Liu L, Ball C, Choi H, May WS, Aboulfatova K, Bergeron AL, Dong JF. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007, 92:121-124. 10.3324/haematol.10262, 17229645.
28. Nguyen TC, Han YY, Kiss JE, Hall MW, Hassett AC, Jaffe R, Orr RA, Janosky J, Carcillo JA. Intensive plasma exchange increases adamts-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med 2008, 36:2878-2887. 10.1097/CCM.0b013e318186aa49, 2772176, 18828196.
29. Pelras S, Delmas Y, Lamireau D, Villega F, Nolent P, Ryman A, Llanas B, Brissaud O, Harambat J. Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome. Pediatr Nephrol 2011, 26:631-635. 10.1007/s00467-010-1721-9, 21161282.
30. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
31. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a european/north american multicenter study. JAMA 1993, 270:2957-2963. 10.1001/jama.1993.03510240069035, 8254858.
32. Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A, Teres D. The logistic organ dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU scoring group. JAMA 1996, 276:802-810. 10.1001/jama.1996.03540100046027, 8769590.
33. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.
34. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the international society of thrombosis and haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004, 32:2416-2421. 10.1097/01.CCM.0000147769.07699.E3, 15599145.
35. Angstwurm MW, Dempfle CE, Spannagl M. New disseminated intravascular coagulation score: A useful tool to predict mortality in comparison with acute physiology and chronic health evaluation ii and logistic organ dysfunction scores. Crit Care Med 2006, 34:314-320. 10.1097/01.CCM.0000196832.27501.B2, 16424708.
36. Veyradier A, Fressinaud E, Sigaud M, Wolf M, Meyer D. A new automated method for von Willebrand factor antigen measurement using latex particles. Thromb Haemost 1999, 81:320-321.
37. Groot E, Fijnheer R, Sebastian SA, de Groot PG, Lenting PJ. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission. J Thromb Haemost 2009, 7:962-969. 10.1111/j.1538-7836.2009.03433.x, 19548905.
38. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 2001, 98:1765-1772. 10.1182/blood.V98.6.1765, 11535510.
39. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for adamts13 assay. Br J Haematol 2005, 129:93-100. 10.1111/j.1365-2141.2005.05420.x, 15801961.
40. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A. Prognostic value of anti-ADAMTS 13 antibody features (ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable adamts 13 activity. Blood 2007, 109:2815-2822.
41. Nguyen TC, Stegmayr B, Busund R, Bunchman TE, Carcillo JA. Plasma therapies in thrombotic syndromes. Int J Artif Organs 2005, 28:459-465.
42. Gando S. Microvascular thrombosis and multiple organ failure. Crit Care Med 2010, 38:35-42.
43. Wang Z, Yu Z, Su J, Cao L, Zhao X, Ruan C. Sepsis-Induced Disseminated Intravascular Coagulation with features of Thrombotic Thrombocytopenic Purpura: a fatal fulminant syndrome. Clin Appl Thromb Hemost 2011, 17:251-253. 10.1177/1076029609357739, 20211920.
44. Mimuro J, Niimura M, Kashiwakura Y, Ishiwata A, Ono T, Ohmori T, Madoiwa S, Okada K, Matsuo O, Sakata Y. Unbalanced expression of ADAMTS13 and von Willebrand factor in mouse endotoxinemia. Thromb Res 2008, 122:91-97. 10.1016/j.thromres.2007.09.011, 18006046.
45. Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 2008, 6:1233-1235. 10.1111/j.1538-7836.2008.02989.x, 2582585, 18433458.
46. Chung MC, Popova TG, Jorgensen SC, Dong L, Chandhoke V, Bailey CL, Popov SG. Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy. J Biol Chem 2008, 283:9531-9542. 10.1074/jbc.M705871200, 18263586.
47. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005, 105:1085-1093.
48. Feys HB, Vandeputte N, Palla R, Peyvandi F, Peerlinck K, Deckmyn H, Lijnen HR, Vanhoorelbeke K. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost 2010, 8:2053-2062. 10.1111/j.1538-7836.2010.03942.x, 20553378.
49. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004, 104:100-106. 10.1182/blood-2004-01-0107, 15026315.
50. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 2005, 29:169-175. 10.1016/j.cyto.2004.10.010, 15652449.
51. Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG, Dong JF, Moake JL. Hemolytic uremic syndrome-associated shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005, 106:4199-4209. 10.1182/blood-2005-05-2111, 1895236, 16131569.
52. Lerolle N, Dunois-Lardé C, Badirou I, Motto DG, Hill G, Bruneval P, Diehl JL, Denis CV, Baruch D. von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture. J Thromb Haemost 2009, 7:843-850. 10.1111/j.1538-7836.2009.03313.x, 19187073.
53. Bockmeyer CL, Reuken PA, Simon TP, Budde U, Lösche W, Bauer M, Birschmann I, Becker JU, Marx G, Claus RA. ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition. Thromb Haemost 2011, 105:145-153.
54. Reiter RA, Varadi K, Turecek PL, Jilma B, Knöbl P. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005, 93:554-558.
55. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005, 115:2752-2761. 10.1172/JCI26007, 1240119, 16200209.
56. Chauhan AK, Walsh MT, Zhu G, Ginsburg D, Wagner DD, Motto DG. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia and thrombosis. Blood 2008, 111:3452-3457. 10.1182/blood-2007-08-108571, 2275014, 18083848.
57. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008, 205:2065-2074. 10.1084/jem.20080130, 2526201, 18695007.
58. Huang J, Motto DG, Bundle DR, Sadler JE. Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood 2010, 116:3653-3659. 10.1182/blood-2010-02-271957, 2981485, 20644116.
59. Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Gårdlund B, Marshall JC, Rhodes A. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008, 34:1935-1947. 10.1007/s00134-008-1266-6, 2995439, 18839141.